Health Status Improvement After Peripheral Vascular Intervention: Insights From the LIBERTY 360 Study

IF 2.1 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS American Journal of Cardiology Pub Date : 2025-05-15 Epub Date: 2025-01-31 DOI:10.1016/j.amjcard.2025.01.017
Ramya C. Mosarla MD , Mohsin Chowdhury MD , Kim G. Smolderen PhD, MSc , Carlos Mena-Hurtado MD , John Spertus MD, MPH , Robert W. Yeh MD, MBA , Eric A. Secemsky MD, MSc
{"title":"Health Status Improvement After Peripheral Vascular Intervention: Insights From the LIBERTY 360 Study","authors":"Ramya C. Mosarla MD ,&nbsp;Mohsin Chowdhury MD ,&nbsp;Kim G. Smolderen PhD, MSc ,&nbsp;Carlos Mena-Hurtado MD ,&nbsp;John Spertus MD, MPH ,&nbsp;Robert W. Yeh MD, MBA ,&nbsp;Eric A. Secemsky MD, MSc","doi":"10.1016/j.amjcard.2025.01.017","DOIUrl":null,"url":null,"abstract":"<div><div>Improving health status is a primary indication for peripheral endovascular intervention (PVI) for symptomatic peripheral arterial disease. The data informing mid- and long-term changes and predictors of health status following PVI are limited. LIBERTY 360, a prospective, nonrandomized, multicenter study evaluated outcomes in patients undergoing PVI. Health status measures were assessed at 30-days, 1 and 3-years using EQ-VAS (0-100,100 best health) and VascuQol-25 (1-7,7 best health), stratified by claudication (Rutherford 2-3), and chronic limb-threatening ischemia (CLTI, Rutherford 4-6). Multivariable regression identified predictors of health status at 1-year. Repeated measures models were constructed based on patients with available data through 3 years. Outcomes including major adverse events, all-cause death, major amputation/death, target vessel/lesion revascularization, and major adverse limb events (MALE)/post-operative death were reported. Claudication (n = 501, 41.6%) had higher baseline VascuQol total scores (4.3 ± 1.3) compared to CLTI (n = 703, 58.4%) (3.8 ± 1.4). The VascuQol total score improved at 30-days with claudication (5.4 ± 1.3, p &lt; 0.0001) and CLTI (4.7 ± 1.4, p &lt; 0.0001). Baseline EQ-VAS was higher with claudication (68.3 ± 19.7) than with CLTI (63.1 ± 20.1). EQ-VAS improved at 30-days with claudication (74.9 ± 17.9, p &lt; 0.0001) and CLTI (68.6 ± 19.2, p-value:&lt;0.0001). Improvements were maintained through 3-years. Baseline health status, history of PVI, and comorbidities predicted health status after PVI. While major adverse events rates were high at 3-years, this was driven by target vessel/lesion revascularization with high rates of freedom from major amputation, all-cause death, and MALE in both groups. In conclusion, PVI is associated with mid- long-term improvements in health status across peripheral arterial disease severity. Baseline characteristics were associated with health status at 1-year and may inform patient selection.</div></div>","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":"243 ","pages":"Pages 22-31"},"PeriodicalIF":2.1000,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Cardiology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0002914925000438","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/31 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Improving health status is a primary indication for peripheral endovascular intervention (PVI) for symptomatic peripheral arterial disease. The data informing mid- and long-term changes and predictors of health status following PVI are limited. LIBERTY 360, a prospective, nonrandomized, multicenter study evaluated outcomes in patients undergoing PVI. Health status measures were assessed at 30-days, 1 and 3-years using EQ-VAS (0-100,100 best health) and VascuQol-25 (1-7,7 best health), stratified by claudication (Rutherford 2-3), and chronic limb-threatening ischemia (CLTI, Rutherford 4-6). Multivariable regression identified predictors of health status at 1-year. Repeated measures models were constructed based on patients with available data through 3 years. Outcomes including major adverse events, all-cause death, major amputation/death, target vessel/lesion revascularization, and major adverse limb events (MALE)/post-operative death were reported. Claudication (n = 501, 41.6%) had higher baseline VascuQol total scores (4.3 ± 1.3) compared to CLTI (n = 703, 58.4%) (3.8 ± 1.4). The VascuQol total score improved at 30-days with claudication (5.4 ± 1.3, p < 0.0001) and CLTI (4.7 ± 1.4, p < 0.0001). Baseline EQ-VAS was higher with claudication (68.3 ± 19.7) than with CLTI (63.1 ± 20.1). EQ-VAS improved at 30-days with claudication (74.9 ± 17.9, p < 0.0001) and CLTI (68.6 ± 19.2, p-value:<0.0001). Improvements were maintained through 3-years. Baseline health status, history of PVI, and comorbidities predicted health status after PVI. While major adverse events rates were high at 3-years, this was driven by target vessel/lesion revascularization with high rates of freedom from major amputation, all-cause death, and MALE in both groups. In conclusion, PVI is associated with mid- long-term improvements in health status across peripheral arterial disease severity. Baseline characteristics were associated with health status at 1-year and may inform patient selection.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
外周血管干预后的健康状况改善:来自LIBERTY 360研究的见解
改善健康状况是外周血管内介入治疗(PVI)对症外周动脉疾病的主要适应症。关于PVI后健康状况中长期变化和预测因素的数据是有限的。LIBERTY- 360是一项前瞻性、非随机、多中心研究,评估了PVI患者的预后。采用EQ-VAS(0-100,100最佳健康状况)和VascuQol-25(1-7,7最佳健康状况)对30天、1年和3年的健康状况进行评估,并根据跛行(Rutherford 2-3)和慢性肢体威胁缺血(CLTI, Rutherford 4-6)进行分层。多变量回归确定了1年健康状况的预测因素。根据患者3年的可用数据构建重复测量模型。结果包括主要不良事件、全因死亡、主要截肢/死亡、靶血管/病变血运重建和主要肢体不良事件/术后死亡。跛行(n = 501,41.6%)的基线VascuQol总分(4.3±1.3)高于CLTI (n = 703,58.4%)(3.8±1.4)。30d时,跛行组VascuQol总分(5.4±1.3分,p < 0.0001)和CLTI总分(4.7±1.4分,p < 0.0001)均有改善。跛行组基线EQ-VAS评分(68.3±19.7)高于CLTI组(63.1±20.1)。EQ-VAS在跛行30天改善(74.9±17.9,p < 0.0001), CLTI改善(68.6±19.2,p值:
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
American Journal of Cardiology
American Journal of Cardiology 医学-心血管系统
CiteScore
4.00
自引率
3.60%
发文量
698
审稿时长
33 days
期刊介绍: Published 24 times a year, The American Journal of Cardiology® is an independent journal designed for cardiovascular disease specialists and internists with a subspecialty in cardiology throughout the world. AJC is an independent, scientific, peer-reviewed journal of original articles that focus on the practical, clinical approach to the diagnosis and treatment of cardiovascular disease. AJC has one of the fastest acceptance to publication times in Cardiology. Features report on systemic hypertension, methodology, drugs, pacing, arrhythmia, preventive cardiology, congestive heart failure, valvular heart disease, congenital heart disease, and cardiomyopathy. Also included are editorials, readers'' comments, and symposia.
期刊最新文献
Emergency Transcatheter Edge-to-Edge Mitral Valve Repair as a Bail-Out Strategy After Failed NeoChord Surgical Repair in Acute Degenerative Mitral Regurgitation Prevalence of Desmoplakin Variants in Patients With Recurrent Myocarditis Cardiovascular Magnetic Resonance-based Tissue Characteristics and Clinical Outcomes in Apical Hypertrophic Cardiomyopathy Economic Evaluation of Transcatheter Versus Surgical Aortic Valve Replacement for Severe Aortic Stenosis in Brazil´s Public Health System: Bridging the Financial Gap Heart Failure Outcomes Among Medicare Beneficiaries Before and During the COVID-19 Pandemic
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1